Pharmacokinetic Properties of Single-Dose Primaquine in Papua New Guinean Children: Feasibility of Abbreviated High-Dose Regimens for Radical Cure of Vivax Malaria
Brioni R Moore, Sam Salman, John Benjamin, Madhu Page-Sharp, Leanne J Robinson, Elizabeth Waita, Kevin T Batty, Peter Siba, Ivo Mueller, Timothy ME Davis, Inoni Betuela
Antimicrobial Agents and Chemotherapy | AMER SOC MICROBIOLOGY | Published : 2014
Since conventional 14-day primaquine (PMQ) radical cure of vivax malaria is associated with poor compliance, and as total dose, not therapy duration, determines efficacy, a preliminary pharmacokinetic study of two doses (0.5 and 1.0 mg/kg of body weight) was conducted in 28 healthy glucose-6-phosphate dehydrogenase-normal Papua New Guinean children, aged 5 to 12 years, to facilitate development of abbreviated high-dose regimens. Dosing was with food and was directly observed, and venous blood samples were drawn during a 168-h postdose period. Detailed safety monitoring was performed for hepatorenal function and hemoglobin and methemoglobin concentrations. Plasma concentrations of PMQ and its..View full abstract
Awarded by National Health and Medical Research Council (NHMRC) of Australia
The study was funded by the Australian Agency for International Development (AusAID) and the National Health and Medical Research Council (NHMRC) of Australia (project grant 634343). B.R.M. is supported by an NHMRC C.J. Martin Overseas Biomedical Fellowship and T.M.E.D. by an NHMRC Practitioner Fellowship.